Breakthrough data from Vatiquinone trials propels PTC Therapeutics stock to 52-week high
PTC Therapeutics Inc. (NASDAQ: PTCT) is experiencing significant momentum within the biotechnology sector following a surge in its stock price to a 52-week high of $40.69. This increase reflects heightened investor confidence driven by the positive clinical outcomes of its Friedreich ataxia (FA) investigational treatment, vatiquinone. Over the past year, the company’s share value has […]